Endometriosis Treatment Market - By Disease Type, By Treatment Type, By Drug Class, By Route of Administration, By Distribution Channel - Global Forecast, 2025 – 2034

Endometriosis Treatment Market Size

The global endometriosis treatment market size was estimated at USD 1.6 billion in 2024. The market is expected to grow from USD 1.8 billion in 2025 to USD 5.4 billion in 2034, at a CAGR of 13.3%. According to World Health Organization, globally 190 million (10%) women of reproductive age are affected with endometriosis, equating to millions of potential patients requiring medical intervention.
 

This significant increase in patient population coupled with growing awareness about the condition and its impact on fertility among patients are supporting the market’s growth. Additionally, pharmaceutical companies are engaged in developing innovative treatments, such as gonadotropin-releasing hormone (GnRH) antagonists and targeted hormonal treatments, thus expanding treatment options for endometriosis.
 

Further, the growing emphasis on women’s health has led to increased healthcare expenditure and efforts towards improving women’s health. This has resulted in improved accessibility to endometriosis diagnostics and treatment. For instance, the Endometriosis Association conducts the Teen Outreach Program that aims in educating teenage girls regarding the importance of early diagnosis and timely interventions for endometriosis. Till date, the organization has distributed 2,577 Teen Outreach educational packages in 34 states. Such initiatives by health organizations and pharmaceutical companies are encouraging more women to seek treatment. Additionally, advancements in drug development, minimally invasive therapies and introduction of hormone therapies are further expected to propel the growth of this market.
 

Endometriosis is a condition in which growth of tissues similar to the lining inside the uterus is observed outside the uterus, resulting in pain, majorly during the menstruation and can cause severe issues like infertility. The treatment aims at managing the symptoms and slowing the disease progression. Common treatments include pain management drugs including non-steroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies.
 

Endometriosis Treatment Market Trends

• The market is experiencing significant growth, driven by several key trends that are shaping its trajectory. One of the primary trends is the increasing prevalence of endometriosis and awareness about the condition through government and health organizations.
   
• For instance, in the U.S., 6.5 million women and girls as young as eight years old suffer from endometriosis, and the global prevalence of the disease has reached approximately 89 million. Thus, the growing prevalence of the disease is leading to an increasing trend in the adoption of endometriosis treatment.
   
• Additionally, due to the increased prevalence and awareness, there is a rise in healthcare expenditure and growing investments in women’s health, fostering the market’s growth. For instance, in February 2025, the Federal Government announced an investment of USD 573 million for addressing the healthcare needs of women living with endometriosis and chronic pelvic pain in Australia. Further, the commitment of government to fund additional 11 specialized endometriosis and pelvic pain clinics, making it to 33 in total within the nation.
   
• Further, there is an increasing shift towards non-invasive and patient-centric solutions. The patients are not only seeking effective treatment but are also looking for convenient and less invasive treatment options, thus further driving the growth.
   
• As endometriosis leads to infertility affecting a broader population, there is a growing emphasis on fertility-focused treatments. Thus, with significant proportion of patients experiencing infertility, the development of therapies that balance symptom control with fertility preservation is gaining traction.
   

Endometriosis Treatment Market Analysis

Based on the disease type, the global market is segmented into superficial peritoneal endometriosis, ovarian endometriomas, deep infiltrating endometriosis and other disease types. The superficial peritoneal endometriosis segment dominated the global market with 41.3% market share in 2024.
 

• Superficial peritoneal endometriosis is the most common form of the disease and is characterized by lesions. For instance, as per an article published by the National Institutes of Health, approximately 80% of women affected with endometriosis have superficial lesions. It affects a large proportion of women diagnosed with endometriosis, making it the dominant disease type in this market.
   
• It is diagnosed easily as it occurs on the peritoneal surface compared to deeper infiltrating forms. This early diagnosis of the superficial peritoneal endometriosis facilitates timely intervention.
   
• For managing superficial peritoneal endometriosis, a broader range of treatment approaches is available, including pain management and hormonal therapies. Thus, the availability of various treatment options facilitates adoption.
   

Based on the treatment type, the global endometriosis treatment market is categorized into hormone therapy and pain medication. The hormone therapy segment was valued at USD 802.9 million in 2024.
 

• Medical professionals frequently recommend oral contraceptives, GnRH agonists, and progestins as the primary interventions to relieve symptoms such as pelvic discomfort, excessive menstrual bleeding, and dysmenorrhea. The increasing interest in hormone therapy within the endometriosis sector is supported by its established effectiveness, straightforward administration, and growing patient preference.
   
• In addition to this, the continuous investment in research and development has resulted in hormonal treatment advancements, including GnRH antagonists with reduced side effects and selective progesterone receptor modulators, which are widening the treatment options and hence driving the market growth.
   
• For example, Orilissa, the inaugural oral medication employing a gonadotropin-releasing hormone (GnRH) antagonist, was launched to address moderate to severe pain linked to endometriosis. The approval of these products is further broadening the spectrum of hormone therapies accessible.
   

Based on the drug class, the global endometriosis treatment market is divided into gonadotropin releasing hormone, NSAIDs, oral contraceptive, and other drug classes. The gonadotropin releasing hormone segment is expected to grow at 13.4% CAGR over the analysis period.
 

• These drugs minimize the symptoms of pelvic pain and heavy menstrual bleeding through hypoeestrogenism and restraining the expansion of endometrial lesions.
   
• Additionally, the development of oral GnRH antagonists like elagolix provides an alternative for managing endometriosis-associated pain. As they provide alternative to injectable medications, these drugs may help improve patient adherence to treatment regimen.
   
• Moreover, with increasing preference for long-term therapies, alongside the shift from traditional GnRH agonists, this segment of the market is growing further..
   
• Furthermore, new formulations of GnRH, in particular, long-acting injectables and oral options, are bettering patient compliance while increasing the availability of treatment.

Based on the route of administration, the global endometriosis treatment market is bifurcated into oral, injectable, and other routes of administration. The oral segment is projected to reach USD 2.9 billion by 2034.
 

• Doctors frequently prescribe oral treatments, including contraceptives, progestins, and NSAIDs, to manage endometriosis symptoms like pain and heavy bleeding, thanks to their ease of use.
   
• The rising availability of GnRH antagonists—known for their superior effectiveness and reduced side effects—is amplifying this demand.  Compared to other treatments, oral therapies are more cost-effective, making them easier to access in both developed and developing countries.
   
• Moreover, due to increased awareness of endometriosis, early diagnosis, and the preference for non-invasive treatments are expected to significantly drive the growth of the oral segment.
   

Based on the distribution channel, the global endometriosis treatment market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held highest market share of 43.8% in 2024.
 

• A wide range of treatments including advanced therapies and hormone medications necessary for patients with severe pain are offered by hospital pharmacies.
   
• Hospital pharmacies offer innovative and newly launched treatments that other retail pharmacies have not yet procured. They provide the most advanced therapeutic options for patients.
   
• Moreover, the educational and follow up components of patient support offered by the hospital pharmacies greatly enhance their leading market share in the endometriosis treatment services.
   
• Further, the complexity of severe forms of diseases or those with comorbidities requires specialized treatments, thus necessitating hospitalization. Thus, as hospitalization increases, there is an increased demand for complex medication regimens. Hospital pharmacies cater to these requirements, thus driving the growth of this segment.

In 2024, the U.S. endometriosis treatment market was valued at USD 582.1 million from USD 522.1 million in 2023 and USD 469.1 million in 2022.
 

• The increased awareness and early diagnosis of endometriosis, encouraged by educational initiatives such as the Teen Outreach Program and the ENPOWR Project, drive the growth of the market. As endometriosis becomes more prevalent, the demand for its treatments surges. The Endometriosis Foundation of America reports that about 1 in 10 U.S. women face endometriosis during their reproductive years, underscoring the urgent need for effective therapies. This program helps to reduce stigma to promote positive treatment behaviors which results in earlier treatments and an increased treatment demand.
   
• Furthermore, improvements in treatment, emphasis on reproductive health safeguarding, and better access to healthcare services have also enhanced market expansion.
   

In Europe endometriosis treatment market, the Germany is expected to experience growth at significant rate during the forecast period.
 

• According to the data from the German Hospital Statistics, in 2022, there were around 32,000 endometriotic stays recorded in German hospitals which comes to about 0.8 cases for 1,000 residents. The growing number of hospitalizations shows an increasing awareness alongside the diagnosis of the disease, which in turn increases the need for better treatment options.
   
• The market is further expected to grow due to the existence of a well-developed healthcare system in Germany that provides patients with various treatment options, as well as the patients being able to receive effective and advanced care.
   
• Moreover, the rising demand for treatment in patients is fueled by the increased focus on women’s health and endometriosis being regarded as a disease of concern which further accelerates spending in research and patient care treatment.
   
• The growth is further driven by Germany’s leadership in medical innovation and research, which has led to the emergence of new treatment options of endometriosis such as novel hormonal therapies.
   

In Asia Pacific endometriosis treatment market, India is projected to experience substantial growth throughout the forecast period.
 

• According to a research article published by National Institutes of Health, endometriosis is estimated to affect 10% of reproductive age women, which is approximately 42 million women in India. The number is rising, which increases the demand for effective treatments.
   
• The availability of diagnostic techniques and greater healthcare accessibility in India are further leading to increased number of diagnosed patients for endometriosis.
  This rise in diagnosis is contributing to increased demand for medical interventions, including hormonal therapies and surgical treatments.
   
• With better awareness of endometriosis, more women are taking up professional care for symptoms of chronic pelvic pain and infertility. As a result, there will be more adoption of treatment and subsequent expansion in the market.
   
• India’s high prevalence of endometriosis, together with increased spending on healthcare and growth in scientific research, creates a high demand for effective solutions. This positions India as a key growth driver in the Asia-Pacific market.
   

In Latin America endometriosis treatment market, Brazil is projected to see significant growth over the analysis period.
 

• A better understanding of endometriosis by health practitioners and the general population has resulted in higher diagnosis rates within Brazil. More women becoming aware of the consequences and symptoms of endometriosis means they are more willing to seek medical care, which is fueling market growth.
   
• The healthcare infrastructure in Brazil have improved over the years, ensuring the availability of advanced treatments available in the country.
   
• Furthermore, the large population of women in the reproductive age in Brazil leads to a greater number of endometriosis cases. This population characteristic creates a large number of patients who need to be managed and treated, which boosts market expansion.
   

In Middle East and Africa endometriosis treatment market, Saudi Arabia is forecasted to experience notable growth in the future.
 

• Improved public understanding and awareness of endometriosis has resulted in higher diagnosis rates in Saudi Arabia. An increasing number of women noticing the symptoms is enhancing the attention towards seeking medical care, which is subsequently increasing the need for treatment options.
   
• Within the Vision 2030 program, the Saudi government is looking to spend more than USD 65 billion to improve the country’s healthcare system including e-health services and health cluster centers. These changes will improve the specialized services available for endometriosis and other ailments.
   
• Improved government policies in women's healthcare services and the availability of treatment gaps are enabling market growth. The focus on health promotion together with health systems integration, leads to effective management of endometriosis.
   

Endometriosis Treatment Market Share

Top 5 players operating in this market includes AstraZeneca, Bayer, Eli Lilly and Company, Pfizer and AbbVie, accounting for approximately 45% of market share. The market is characterized by a diverse competitive landscape driven by various factors, including technological advancements, patient demand for effective treatments, and increasing awareness of the disease. Leading pharmaceutical companies dominate the market due to their comprehensive product portfolios, established brand recognition, and large-scale distribution networks. These companies hold significant market share by offering a range of hormonal therapies, pain management options, and non-hormonal treatments.
 

Furthermore, the market is experiencing growth due to rising global awareness of endometriosis, improved access to healthcare, and advancements in diagnostic technologies. The growing emphasis on personalized treatment solutions and digital health innovations further fuels the market’s expansion, creating opportunities for both large and small players in the industry.
 

Endometriosis Treatment Market Companies

Few of the prominent players operating in the endometriosis treatment industry include:

• AbbVie
• Astellas Pharma
• AstraZeneca
• Bayer
• Eli Lilly and Company
• ObsEva
• Pfizer
• Teva Pharmaceutical Industries
• TerSera Therapeutics
• Zydus Healthcare Limited
   

AbbVie released ORILISSA (elagolix) which is an oral dosage form of the first GnRH antagonist designed to treat moderate to severe endometriosis pain. As an oral therapy, ORILISSA increases patient compliance, further reinforcing AbbVie's leadership in women's health and innovative solutions to treat endometriosis.
 

Bayer has significant market presence in the hormonal treatment of endometriosis with Visanne (dienogest), a progestin therapy that was created to aid in managing the pain associated with endometriosis. Bayer continues to dominate this area due to its vast established international distribution network.
 

Endometriosis Treatment Industry News

• In January 2025, Celmatix Therapeutics announced a novel drug program featuring a Jun-N-terminal kinase (JNK) inhibitor designed to target pain and inflammation in endometriosis. Developed through the DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine, this drug aims to fill a critical gap in first-line treatments for endometriosis. This helped the company position itself as a leader in innovative women's health therapies and potentially open new market segments in endometriosis and reproductive health.
   
• In March 2024, Israel-based Gynica initiated a Phase I trial for its cannabinoid-based therapies, IntraVagS301 and IntraVagS302, for the treatment of endometriosis, with the first patient expected to be dosed by the end of the year. By pioneering cannabinoid-based treatments for endometriosis, Gynica aimed to differentiate itself in the market and capture attention with a potentially unique approach to manage the disease.
   
• In August 2022, Myovant Sciences and Pfizer announced that the FDA approved MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a once-daily pill for managing moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months. This approval helped the companies gain a competitive advantage in the endometriosis market and generate revenue growth.
   

The endometriosis treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Superficial peritoneal endometriosis
• Ovarian endometriomas
• Deep infiltrating endometriosis
• Other disease types

Market, By Treatment Type

• Hormone therapy
• Pain medication

Market, By Drug Class

• Gonadotropin releasing hormone
• NSAIDs
• Oral contraceptive
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE